Analyzing Two Decades of Leukemia Mortality in the U.S. (1999-2020).

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-13 DOI:10.1016/j.clml.2025.03.006

Nouman Aziz, Waseem Nabi, Muzamil Khan, Abu Huraira Bin Gulzar, Shree Rath, Asad Ali Ahmed Cheema, Mirza Ammar Arshad, Fatima Hussain, Abraham Titus, Amar Lal, Faiz Anwar

{"title":"Analyzing Two Decades of Leukemia Mortality in the U.S. (1999-2020).","authors":"Nouman Aziz, Waseem Nabi, Muzamil Khan, Abu Huraira Bin Gulzar, Shree Rath, Asad Ali Ahmed Cheema, Mirza Ammar Arshad, Fatima Hussain, Abraham Titus, Amar Lal, Faiz Anwar","doi":"10.1016/j.clml.2025.03.006","DOIUrl":null,"url":null,"abstract":"Background: Leukemia is a hematologic malignancy with varying incidence and outcomes influenced by demographic and geographic factors. Understanding mortality trends and disparities is essential for guiding public health policy.Objective: To analyze leukemia mortality trends in the U.S. from 1999 to 2020, focusing on age-adjusted mortality rates (AAMRs), disparities, and geographic patterns.Methods: Data from the CDC WONDER database were analyzed, covering leukemia-related deaths (ICD-10 codes C91-C95). Age groups were stratified into < 45 and ≥ 45 years. Joinpoint regression models estimated annual percentage changes (APCs). Data were examined by demographics, census regions, and urbanization levels.Results: AAMRs for individuals ≥ 45 years declined by an APC of -0.90% but increased slightly from 2018 to 2020. Males, non-Hispanic Whites, and rural populations exhibited higher AAMRs. Among individuals < 45 years old, AAMRs consistently declined with minimal disparities. Acute myeloid leukemia was predominant among older adults, while acute lymphoblastic leukemia affected younger populations.Conclusion: Despite overall declines in leukemia mortality, persistent disparities across age, gender, and geographic regions highlight inequities in healthcare access. Strategic interventions are required to address these gaps and enhance leukemia care nationwide.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.03.006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Leukemia is a hematologic malignancy with varying incidence and outcomes influenced by demographic and geographic factors. Understanding mortality trends and disparities is essential for guiding public health policy.

Objective: To analyze leukemia mortality trends in the U.S. from 1999 to 2020, focusing on age-adjusted mortality rates (AAMRs), disparities, and geographic patterns.

Methods: Data from the CDC WONDER database were analyzed, covering leukemia-related deaths (ICD-10 codes C91-C95). Age groups were stratified into < 45 and ≥ 45 years. Joinpoint regression models estimated annual percentage changes (APCs). Data were examined by demographics, census regions, and urbanization levels.

Results: AAMRs for individuals ≥ 45 years declined by an APC of -0.90% but increased slightly from 2018 to 2020. Males, non-Hispanic Whites, and rural populations exhibited higher AAMRs. Among individuals < 45 years old, AAMRs consistently declined with minimal disparities. Acute myeloid leukemia was predominant among older adults, while acute lymphoblastic leukemia affected younger populations.

Conclusion: Despite overall declines in leukemia mortality, persistent disparities across age, gender, and geographic regions highlight inequities in healthcare access. Strategic interventions are required to address these gaps and enhance leukemia care nationwide.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.